tiprankstipranks
Trending News
More News >
Elevance Health (ELV)
NYSE:ELV
US Market
Advertisement

Elevance Health (ELV) Stock Forecast & Price Target

Compare
2,732 Followers
See the Price Targets and Ratings of:

ELV Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
12 Buy
5 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$367.81
▲(28.61%Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $367.81 with a high forecast of $505.00 and a low forecast of $297.00. The average price target represents a 28.61% change from the last price of $285.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"296":"$296","549":"$549","359.25":"$359.3","422.5":"$422.5","485.75":"$485.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":505,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$505.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":367.81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$367.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":297,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$297.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[296,359.25,422.5,485.75,549],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,395.76,404.1630769230769,412.56615384615384,420.96923076923076,429.3723076923077,437.7753846153846,446.17846153846153,454.58153846153846,462.9846153846154,471.3876923076923,479.79076923076923,488.19384615384615,496.5969230769231,{"y":505,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,395.76,393.61,391.46,389.31,387.15999999999997,385.01,382.86,380.71,378.56,376.41,374.26,372.11,369.96,{"y":367.81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,395.76,388.1630769230769,380.56615384615384,372.96923076923076,365.3723076923077,357.7753846153846,350.17846153846153,342.58153846153846,334.9846153846154,327.3876923076923,319.79076923076923,312.19384615384615,304.5969230769231,{"y":297,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":526.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":523.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":548.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":504.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":405.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":365.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":392.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":393.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":430.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":406.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":375.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":395.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$505.00Average Price Target$367.81Lowest Price Target$297.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ELV
TipRanks AITipRanks
Not Ranked
TipRanks
$315
Buy
10.15%
Upside
Upgraded
07/29/25
Elevance Health's overall stock score is primarily supported by strong financial performance and favorable valuation metrics. However, bearish technical analysis and challenges highlighted in the earnings call, such as cost pressures and membership declines, moderate the score. The company's ability to navigate these challenges will be crucial for its future performance.
UBS
$435
Buy
52.11%
Upside
Reiterated
07/28/25
Elevance Health's 2026 EPS could land 'in low to mid 30s,' says UBSElevance Health's 2026 EPS could land 'in low to mid 30s,' says UBS
Robert W. Baird Analyst forecast on ELV
Michael HaRobert W. Baird
Robert W. Baird
$492$297
Hold
3.85%
Upside
Reiterated
07/25/25
Elevance Health price target lowered to $297 from $492 at BairdElevance Health price target lowered to $297 from $492 at Baird
J.P. Morgan Analyst forecast on ELV
Lisa GillJ.P. Morgan
J.P. Morgan
$472$384
Buy
34.28%
Upside
Reiterated
07/22/25
J.P. Morgan Remains a Buy on Elevance Health (ELV)JPMorgan analyst Lisa Gill lowered the price target on Elevance (NYSE: ELV) to $384.00 (from $472.00) while maintaining a Overweight rating.
Barclays
$358$327
Buy
14.34%
Upside
Reiterated
07/22/25
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Veeva Systems (NYSE: VEEV) and Elevance Health (NYSE: ELV)
Argus Research Analyst forecast on ELV
David ToungArgus Research
Argus Research
Hold
Downgraded
07/21/25
Elevance Health downgraded to Hold from Buy at ArgusElevance Health downgraded to Hold from Buy at Argus
RBC Capital Analyst forecast on ELV
Ben HendrixRBC Capital
RBC Capital
$478$311
Buy
8.75%
Upside
Reiterated
07/21/25
RBC Capital Reaffirms Their Buy Rating on Elevance Health (ELV)
Bernstein Analyst forecast on ELV
Lance WilkesBernstein
Bernstein
$487$445
Buy
55.61%
Upside
Reiterated
07/21/25
Bernstein Remains a Buy on Elevance Health (ELV)
TD Cowen
$484$330
Buy
15.39%
Upside
Reiterated
07/21/25
Elevance Health: Buy Rating Affirmed Amid Growth Potential in Non-HIX Segments and Temporary Earnings Boosts
Morgan Stanley Analyst forecast on ELV
Erin WrightMorgan Stanley
Morgan Stanley
$316
Hold
10.50%
Upside
Reiterated
07/18/25
Elevance Health: Hold Rating Amid Elevated Utilization and Market Uncertainty
Jefferies Analyst forecast on ELV
David WindleyJefferies
Jefferies
$488$370
Buy
29.38%
Upside
Reiterated
07/18/25
Jefferies Remains a Buy on Elevance Health (ELV)
Truist Financial Analyst forecast on ELV
David S MacdonaldTruist Financial
Truist Financial
$440$365
Buy
27.63%
Upside
Reiterated
07/18/25
Elevance Health price target lowered to $440 from $500 at TruistElevance Health price target lowered to $440 from $500 at Truist
Cantor Fitzgerald Analyst forecast on ELV
Sarah JamesCantor Fitzgerald
Cantor Fitzgerald
$485$400
Buy
39.87%
Upside
Reiterated
07/18/25
Cantor Fitzgerald Sticks to Their Buy Rating for Elevance Health (ELV)
Bank of America Securities Analyst forecast on ELV
Kevin FischbeckBank of America Securities
Bank of America Securities
$350$330
Hold
15.39%
Upside
Reiterated
07/18/25
Bank of America Securities Remains a Hold on Elevance Health (ELV)
Leerink Partners Analyst forecast on ELV
Whit MayoLeerink Partners
Leerink Partners
$510$310
Hold
8.40%
Upside
Downgraded
07/18/25
Cautious Outlook for Elevance Health Amidst Earnings Growth Challenges and Sector Risks
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ELV
TipRanks AITipRanks
Not Ranked
TipRanks
$315
Buy
10.15%
Upside
Upgraded
07/29/25
Elevance Health's overall stock score is primarily supported by strong financial performance and favorable valuation metrics. However, bearish technical analysis and challenges highlighted in the earnings call, such as cost pressures and membership declines, moderate the score. The company's ability to navigate these challenges will be crucial for its future performance.
UBS
$435
Buy
52.11%
Upside
Reiterated
07/28/25
Elevance Health's 2026 EPS could land 'in low to mid 30s,' says UBSElevance Health's 2026 EPS could land 'in low to mid 30s,' says UBS
Robert W. Baird Analyst forecast on ELV
Michael HaRobert W. Baird
Robert W. Baird
$492$297
Hold
3.85%
Upside
Reiterated
07/25/25
Elevance Health price target lowered to $297 from $492 at BairdElevance Health price target lowered to $297 from $492 at Baird
J.P. Morgan Analyst forecast on ELV
Lisa GillJ.P. Morgan
J.P. Morgan
$472$384
Buy
34.28%
Upside
Reiterated
07/22/25
J.P. Morgan Remains a Buy on Elevance Health (ELV)JPMorgan analyst Lisa Gill lowered the price target on Elevance (NYSE: ELV) to $384.00 (from $472.00) while maintaining a Overweight rating.
Barclays
$358$327
Buy
14.34%
Upside
Reiterated
07/22/25
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Veeva Systems (NYSE: VEEV) and Elevance Health (NYSE: ELV)
Argus Research Analyst forecast on ELV
David ToungArgus Research
Argus Research
Hold
Downgraded
07/21/25
Elevance Health downgraded to Hold from Buy at ArgusElevance Health downgraded to Hold from Buy at Argus
RBC Capital Analyst forecast on ELV
Ben HendrixRBC Capital
RBC Capital
$478$311
Buy
8.75%
Upside
Reiterated
07/21/25
RBC Capital Reaffirms Their Buy Rating on Elevance Health (ELV)
Bernstein Analyst forecast on ELV
Lance WilkesBernstein
Bernstein
$487$445
Buy
55.61%
Upside
Reiterated
07/21/25
Bernstein Remains a Buy on Elevance Health (ELV)
TD Cowen
$484$330
Buy
15.39%
Upside
Reiterated
07/21/25
Elevance Health: Buy Rating Affirmed Amid Growth Potential in Non-HIX Segments and Temporary Earnings Boosts
Morgan Stanley Analyst forecast on ELV
Erin WrightMorgan Stanley
Morgan Stanley
$316
Hold
10.50%
Upside
Reiterated
07/18/25
Elevance Health: Hold Rating Amid Elevated Utilization and Market Uncertainty
Jefferies Analyst forecast on ELV
David WindleyJefferies
Jefferies
$488$370
Buy
29.38%
Upside
Reiterated
07/18/25
Jefferies Remains a Buy on Elevance Health (ELV)
Truist Financial Analyst forecast on ELV
David S MacdonaldTruist Financial
Truist Financial
$440$365
Buy
27.63%
Upside
Reiterated
07/18/25
Elevance Health price target lowered to $440 from $500 at TruistElevance Health price target lowered to $440 from $500 at Truist
Cantor Fitzgerald Analyst forecast on ELV
Sarah JamesCantor Fitzgerald
Cantor Fitzgerald
$485$400
Buy
39.87%
Upside
Reiterated
07/18/25
Cantor Fitzgerald Sticks to Their Buy Rating for Elevance Health (ELV)
Bank of America Securities Analyst forecast on ELV
Kevin FischbeckBank of America Securities
Bank of America Securities
$350$330
Hold
15.39%
Upside
Reiterated
07/18/25
Bank of America Securities Remains a Hold on Elevance Health (ELV)
Leerink Partners Analyst forecast on ELV
Whit MayoLeerink Partners
Leerink Partners
$510$310
Hold
8.40%
Upside
Downgraded
07/18/25
Cautious Outlook for Elevance Health Amidst Earnings Growth Challenges and Sector Risks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

1 Month
xxx
Success Rate
13/24 ratings generated profit
54%
Average Return
+0.65%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.17% of your transactions generating a profit, with an average return of +0.65% per trade.
3 Months
xxx
Success Rate
23/40 ratings generated profit
57%
Average Return
+0.37%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.50% of your transactions generating a profit, with an average return of +0.37% per trade.
1 Year
Success Rate
20/29 ratings generated profit
69%
Average Return
+15.57%
reiterated a buy rating 2 days ago
Copying A.J. Rice's trades and holding each position for 1 Year would result in 68.97% of your transactions generating a profit, with an average return of +15.57% per trade.
2 Years
xxx
Success Rate
24/29 ratings generated profit
83%
Average Return
+38.81%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 82.76% of your transactions generating a profit, with an average return of +38.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
1
6
Buy
18
22
26
32
31
Hold
5
5
4
4
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
27
30
37
44
In the current month, ELV has received 37 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 367.81.
Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $5.66 with a range of $4.47 to $8.69. The previous quarter’s EPS was $8.84. ELV beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.95% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.
Next quarter’s earnings estimate for ELV is $5.66 with a range of $4.47 to $8.69. The previous quarter’s EPS was $8.84. ELV beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.95% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $49.26B with a range of $47.89B to $50.55B. The previous quarter’s sales results were $49.78B. ELV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.
Next quarter’s sales forecast for ELV is $49.26B with a range of $47.89B to $50.55B. The previous quarter’s sales results were $49.78B. ELV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 367.81.
    What is ELV’s upside potential, based on the analysts’ average price target?
    Elevance Health has 28.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ELV a Buy, Sell or Hold?
          Elevance Health has a consensus rating of Moderate Buy which is based on 12 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Elevance Health’s price target?
            The average price target for Elevance Health is 367.81. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $505.00 ,the lowest forecast is $297.00. The average price target represents 28.61% Increase from the current price of $285.98.
              What do analysts say about Elevance Health?
              Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of ELV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis